Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
Delord JP, Bennouna J, Artru P, Perrier H, Husseini F, Desseigne F, François E, Faroux R, Smith D, Piedbois P, Naman H, Douillard JY, Bugat R. Delord JP, et al. Among authors: desseigne f. Br J Cancer. 2007 Aug 6;97(3):297-301. doi: 10.1038/sj.bjc.6603889. Epub 2007 Jul 17. Br J Cancer. 2007. PMID: 17637682 Free PMC article. Clinical Trial.
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, de Gramont A. André T, et al. Among authors: desseigne f. J Clin Oncol. 1999 Nov;17(11):3560-8. doi: 10.1200/JCO.1999.17.11.3560. J Clin Oncol. 1999. PMID: 10550155 Clinical Trial.
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.
Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, Gaudin JL, Lledo G, Mackiewicz R, Gouttebel MC, Moindrot H, Boyer JD, Chassignol L, Stremsdoerfer N, Desseigne F, Moreau JM, Hedelius F, Moraillon A, Chapuis F, Bleuse JP, Barbier Y, Heilmann MO, Valette PJ. Trillet-Lenoir V, et al. Among authors: desseigne f. Br J Radiol. 2002 Nov;75(899):903-8. doi: 10.1259/bjr.75.899.750903. Br J Radiol. 2002. PMID: 12466256
Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Duffour J, Gourgou S, Desseigne F, Debrigode C, Mineur L, Pinguet F, Poujol S, Chalbos P, Bressole F, Ychou M. Duffour J, et al. Among authors: desseigne f. Cancer Chemother Pharmacol. 2007 Aug;60(3):383-9. doi: 10.1007/s00280-006-0372-9. Epub 2006 Nov 24. Cancer Chemother Pharmacol. 2007. PMID: 17124595 Clinical Trial.
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quénet F, Portier G, Nordlinger B. Ychou M, et al. Among authors: desseigne f. Cancer Chemother Pharmacol. 2008 Jul;62(2):195-201. doi: 10.1007/s00280-007-0588-3. Epub 2007 Sep 28. Cancer Chemother Pharmacol. 2008. PMID: 17901955 Clinical Trial.
Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.
de la Fouchardière C, Négrier S, Labrosse H, Martel Lafay I, Desseigne F, Méeus P, Tavan D, Petit-Laurent F, Rivoire M, Pérol D, Carrie C. de la Fouchardière C, et al. Among authors: desseigne f. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):409-13. doi: 10.1016/j.ijrobp.2009.05.008. Epub 2010 Jan 29. Int J Radiat Oncol Biol Phys. 2010. PMID: 20116933 Clinical Trial.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. Conroy T, et al. Among authors: desseigne f. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923. N Engl J Med. 2011. PMID: 21561347 Free article. Clinical Trial.
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M. Assenat E, et al. Among authors: desseigne f. Oncologist. 2011;16(11):1557-64. doi: 10.1634/theoncologist.2011-0141. Epub 2011 Oct 20. Oncologist. 2011. PMID: 22016477 Free PMC article. Clinical Trial.
71 results